Physician profile
Alex Gold
NPI 1114924792
$12,563.09
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $1,310 · 2021: $2,836 · 2022: $2,913 · 2023: $2,913 · 2024: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907 · Education: $20.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.72 |
| Education | $20.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,409.73 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,492.66 | 2019-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $1,036.51 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $638.83 | 2022-2023 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $605.84 | 2021-2024 | |
| Lilly USA, LLC | $456.00 | 2019-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $284.62 | 2021-2024 | |
| Ibsa Pharma INC. | $276.61 | 2019-2022 | |
| Allergan, INC. | $270.97 | 2019-2021 | |
| Novo Nordisk INC | $269.41 | 2020-2024 | Wegovy |
| Novartis Pharmaceuticals Corporation | $255.80 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $245.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.64 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Horizon Therapeutics Plc | $217.86 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $201.07 | 2024 | Rexulti |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.